SUMMARY A randomised double blind clinical trial was undertaken in the UK and Ireland to compare ranitidine 300 mg given as a single bed time tablet with raniditine 150 mg twice daily in the acute treatment of duodenal ulcers. Of the 594 patients with endoscopically diagnosed duodenal ulcer entered into the trial, 424 patients had complete endoscopic findings on which healing rates at four weeks were determined. By this time 156 of 201 (78%) patients healed with ranitidine 300 mg nocte compared with 186 of 223 (83%) receiving ranitidine 150 mg twice daily (p=028). After eight weeks of treatment 97% of the patients in each group were healed. The healing rates for smokers and non-smokers did not differ significantly at either four or eight weeks. Each regimen was equally effective in reducing day and night-time pain. Adverse events were reported in 23 patients overall; 12 were withdrawn from the trial. Minor abnormalities in liver function tests were noted in three patients. The trial confirmed that a single dose of ranitidine 300 mg given at night is a safe, effective alternative treatment to ranitidine 150 mg bd for the acute treatment of duodenal ulcer.
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The importance of increased nocturnal gastric acid secretion in the pathophysiology of duodenal ulceration has been considered for many years and provided the basis for Dragstedt's proposal that such hypersecretion could be controlled by vagotomy.1 2 The effect of vagotomy is not, however, confined to an effect on nocturnal gastric acid secretion as it reduces gastric acidity to all forms of stimulation3 4 over the entire 24 hour period.5 6 Dosage regimens for the histamine-H2-receptor antagonists have sought to mimic this reduction in both day and night time secretion to achieve ulcer healing.
In a carefully controlled study of 24 hour intragastric acidity in patients with recently healed duodenal ulcers, ranitidine 150 mg morning and evening was found to reduce day and night time acidity by approximately 55%. This reduction was similar to that achieved by cimetidine 200 mg tds plus 400 mg nocte.7 Clinical trials in duodenal ulcer have confirmed that the healing rates were also similar for the two drugs.8
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HEALING RATES
The effect of ranitidine 300 mg nocte on ulcer healing at four weeks was similar to ranitidine 150 mg bd (78% and 83% respectively; p=028). By eight weeks the cumulative healing rate in both groups had reached 97% (Table 3 ). The differences (Table 4) . There were no differences in pain relief between the two treatment regimens: by four weeks, 88% of patients receiving 300 mg nocte and 91% receiving 150 mg bd were free of day time ulcer related pain (p>005).
The proportion free of night time pain was also similar in both groups (89% vs 95%; p>005).
ADVERSE EVENTS
Twenty nine adverse events were reported by 23 patients, 12 of whom were withdrawn from the study. These are summarised in Table 5 . One 68 year old man sustained a cardiac arrest and died at three days into the trial. He had a past history of myocardial infarction and his pretreatment examination revealed cardiomegaly and a pansystolic murmur. A 27 year old male patient receiving ranitidine 300 mg nocte was found at review (five weeks) to have a benign breast nodule histologically ulcers. The present trial confirmed the effectiveness of ranitidine 300 mg nocte in a large number of patients.
The healing rate of 78% in the group taking 300 mg at night was comparable with those at four weeks in previous trials which evaluated the use of ranitidine 150 mg bd for the treatment of duodenal ulcer. In a review of published data Meyrick-Thomas and Misiewicz8 found that in double blind placebo controlled trials 78% (375/482) healed at four weeks with ranitidine 150 mg twice daily compared with 37% (169/461) on placebo. In single blind trials comparing ranitidine and cimetidine the mean healing rates for ranitidine 150 mg bd and cimetidine 1 g/day were 74% (407/549) and 68% (364/535 patients) respectively. In addition the present results confirm the finding of Ireland et all( and Brackmann et al'2 that the two treatment regimens evaluated are equivalent in terms of ulcer healing.
Recent studies of the effect of ranitidine on 24 hour intragastric acidity indicate that both the degree and the duration of inhibition of gastric acid secretion may play a role in ulcer healing and the prevention of ulcer recurrence. Dammann and Lee, Reed, Crowe, Mclsaac, and Wood colleagues'4 found that ranitidine 300 mg at night reduced 24 hour gastric acidity by 75% in volunteers. This dosage also reduced acidity by 62% in patients with duodenal ulceration9 but in both studies the overall effect was greatest in the overnight period (85%-95% inhibition) while daytime acid suppression was relatively modest and did not last beyond midday. Twice daily administration of 150 mg reduces acidity through the whole 24 hour period.7 Another study'5 found that 150 mg ranitidine given at bedtime decreased mean 24 hour intragastric acidity by 42% compared with placebo treatment in duodenal ulcer patients. There was a significant decrease in intragastric acidity which lasted from 2400 until 0900, with no significant subsequent change (1000 to 2300 hours). Ranitidine 300 mg at night thus inhibits intragastric acidity for some three to four hours longer and to a greater extent than 150 mg ranitidine but during the rest of the day normal concentrations of acid are present in the stomach. The recent study by Ireland et all" in 102 patients found that the larger nocturnal dose was more effective in smokers (96% healed four weeks) than the twice daily regimen (75% healed four week, p<0-01). The present study showed a small trend in the opposite direction although this did not reach statistical significance in the larger number of patients studied. In neither study, however, was the question of an adverse effect of smoking directly addressed by stratification for smokers and non-smokers during randomisation.
Ippoliti et al'6 carried out an analysis of data from clinical trials where the effect of smoking was reported and noted a median 20% difference in ulcer healing between non-smokers and smokers irrespective of treatment regimen. Another clinical trial stratified 123 patients for sex and smoking before randomisation to ranitidine, cimetidine, or oxmetidine. They also assessed smoking habits during the acute treatment and follow up over 12 months. Analysis of the data revealed that smoking adversely affected healing and that subsequent relapse rates were significantly higher in smokers.
Boyd, Saunders, and Wormsley'8 suggested that this finding was because of decreased inhibition of nocturnal acid secretion in smokers. Studies of acid suppression by H2-antagonists in smokers with duodenal ulcer disease have recently shown a reduced effect compared with non smokers but nocturnal doses of H2-antagonists were more effective in smokers than the twice daily dose. '9 Therefore, the finding in the present study of equivalent healing rates in smokers and nonsmokers taking ranitidine 150 mg twice daily may be regarded as an unexpected chance finding. The difference in healing rates between 300 mg at night and 150 mg twice daily in the present study is, however, small in both smokers and non-smokers. Short term healing can thus be achieved using either a single dose of ranitidine 300 mg given at bedtime or ranitidine 150 mg twice daily.
The frequency of adverse reactions observed in the group of patients given the once daily regimen was similar to the frequency in patients given the twice daily treatment. This finding is in keeping with the known safety profile of ranitidine and the lack of dose dependent adverse effects observed in Zollinger Ellison patients treated with ranitidine up to 6 g/day.
The present findings are consistent with the hypothesis that adequate suppression of nocturnal acid secretion is sufficient to heal most duodenal ulcers in four to eight weeks. Treatment with 300 mg of ranitidine at night is a safe, effective alternative to the twice daily regimen over which it may have a benefit in terms of patient compliance. 
